Results 41 to 50 of about 115,328 (341)

Age‐Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone

Journal of Bone and Mineral Research, 2019
Fibrous dysplasia (FD) is a mosaic disease in which bone is replaced with fibro‐osseous tissue. Lesions expand during childhood, reaching final burden by age 15 years.
P. Florenzano, Kristen S. Pan, Sydney M Brown, S. Paul, H. Kushner, L. Guthrie, L. F. de Castro, M. Collins, A. Boyce   +8 more
semanticscholar   +1 more source

ATYPICAL FRACTURES DUE TO LONG TREATMENT WITH BISPHOSPHONATES (CRITICAL REVIEW)

Travmatologiâ i Ortopediâ Rossii, 2013
This paper reviews the evidence for an association between atypical subtrochanteric fractures and long-term bisphosphonate use. A PubMed search of literature was performed.
G. S. Golubev
doaj   +1 more source

Development of Bone Targeting Drugs. [PDF]

, 2017
The skeletal system, comprising bones, ligaments, cartilage and their connective tissues, is critical for the structure and support of the body. Diseases that affect the skeletal system can be difficult to treat, mainly because of the avascular cartilage
Alméciga-Díaz, Carlos J., Mackenzie, William G., Mason, Robert W., Orii, Tadao, Sawamoto, Kazuki, Stapleton, Molly, Tomatsu, Shunji   +6 more
core   +2 more sources

Therapeutic potential of bisphosphonates - review of medical indications, mechanism of action, interactions and adverse effects

Journal of Education, Health and Sport
Introduction: Bisphosphonates are pharmacological agents that inhibit bone resorption by targeting osteoclasts, thereby increasing bone density and reducing fracture risk.
Agnieszka Mikosińska, Mateusz Litwin, Jakub Parys, Patrycja Kałuziak, Aleksandra Witek, Martyna Kaźmierczak, Stanisław Jesionek, Marta Jajczak, Maciej Mossakowski   +8 more
doaj   +1 more source

Bisphosphonates and osteonecrosis of jaws

Journal of Indian Academy of Oral Medicine and Radiology, 2012
Bisphosphonates are used to treat osteoporosis. Paget disease of bone and other metabolic bone diseases, multiple myeloma, and skeletal events associated with metastatic neoplasms- In 2003, the first reports describing osteonecrosis of the jaw (ONJ) in ...
Geetha Vijay, Vijay Raghavan
doaj   +1 more source

Changes in the utilization of osteoporosis drugs after the 2010 FDA bisphosphonate drug safety communication

Saudi Pharmaceutical Journal, 2018
Introduction: In October 2010, the US Food and Drug Administration (FDA) issued a safety communication regarding the risks of atypical fractures of the femur, with bisphosphonates drugs.
Bander Balkhi, Enrique Seoane-Vazquez, Rosa Rodriguez-Monguio   +2 more
doaj   +1 more source

Non-bisphosphonate inhibitors of isoprenoid biosynthesis identified via computer-aided drug design. [PDF]

, 2011
The relaxed complex scheme, a virtual-screening methodology that accounts for protein receptor flexibility, was used to identify a low-micromolar, non-bisphosphonate inhibitor of farnesyl diphosphate synthase.
Cao, Rong, Durrant, Jacob D, Gorfe, Alemayehu A, Li, Jikun, McCammon, J Andrew, Oldfield, Eric, Sankovsky, Anna, Zhu, Wei   +7 more
core   +2 more sources

The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis

Annals of Geriatric Medicine and Research, 2016
Background: Osteoporosis is commonly treated with bisphosphonates. These drugs promote osteoclast apoptosis, which suppresses bone resorption. However, the probability of side effects increases with long-term use of bisphosphonates.
Seo Young Lee, Kyoung Min Kim, Sung Hye Kong, Tae Jung Oh, Jae Hoon Moon, Sung Hee Choi, Soo Lim, Hak Chul Jang   +7 more
doaj   +1 more source

Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis [PDF]

, 2006
BACKGROUND: Treatment with glucocorticoids is associated with bone loss starting soon after therapy is initiated and an increased risk of fracture. METHODS: We performed a randomized, double-placebo, double-blind clinical trial of 18 months' duration ...
Ale Algra, Anne-Margriet Huisman, Ans C.M. Oostveen, Ben A.C. Dijkmans, Chris E.D. de Laet, de Nijs RN, Erik Buskens, George A.W. Bruyn, Johannes W.G. Jacobs, Johannes W.J. Bijlsma, Michel BA, Piet P.M.M. Geusens, Roland F.J. Laan, Ron N.J. de Nijs, Willem F. Lems   +14 more
core   +4 more sources

Prevention of osteoporotic refractures in regional Australia [PDF]

, 2017
Objective: Clinical guidelines recommend that patients who sustain a minimal trauma fracture (MTF) should receive a bone mineral density (BMD) scan and bisphosphonate (or equivalent) therapy if diagnosed with osteoporosis.
Davidson, E, Doyle, Z, Fielding, K, McGirr, J, Seal, A   +4 more
core   +2 more sources